Evidence map›Paper›PMID 31040112›Full record

ArticleBlood advances2019

Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.

Nickolas Steinauer, Chun Guo, Chunfa Huang, Madeline Wong, Yifan Tu, Carl E Freter, Jinsong Zhang

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. IntegratedCells · 2021
    Article
  16. Article
  17. Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
    Review
  18. The transcriptional corepressor CBFA2T3 inhibits all-The Journal of biological chemistry · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nickolas SteinauerDepartment of Pharmacology & Physiology, and.ORCID 0000-0002-7966-7005
Chun GuoDepartment of Pharmacology & Physiology, and.ORCID 0000-0002-2409-3999
Chunfa HuangDivision of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO.
Madeline WongDepartment of Pharmacology & Physiology, and.ORCID 0000-0001-5875-1534
Yifan TuDivision of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO.
Carl E FreterDivision of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO.
Jinsong ZhangDepartment of Pharmacology & Physiology, and.ORCID 0000-0002-8798-7316
Saint Louis University · US

Funding

Pharmacological Sciences Training GrantT32GM008306 · NIGMS · SAINT LOUIS UNIVERSITY · PI EGAN, TERRANCE M, WALKER, JOHN K. · 1990 to 2020
$3.6M
Aberrant hematopoiesis: E proteins and AML1-ETO in leukemogenesisR01HL093195 · NHLBI · UNIVERSITY OF CINCINNATI · PI ZHANG, JINSONG · 2009 to 2013
$1.9M
Human HDAC3: mechanism of activation and proteasomal degradationR21CA178513 · NCI · SAINT LOUIS UNIVERSITY · PI ZHANG, JINSONG · 2014 to 2015
$362k
NCI NIH HHS R21 CA178513NHLBI NIH HHS R01 HL093195NIGMS NIH HHS T32 GM008306
6 · The paper itself

Abstract

CBFA2T3 is a master transcriptional coregulator in hematopoiesis. In this study, we report novel functions of CBFA2T3 in acute myeloid leukemia (AML) relapse. CBFA2T3 regulates cell-fate genes to establish gene expression signatures associated with leukemia stem cell (LSC) transformation and relapse. Gene set enrichment analysis showed that CBFA2T3 expression marks LSC signatures in primary AML samples. Analysis of paired primary and relapsed samples showed that acquisition of LSC gene signatures involves cell type-specific activation of CBFA2T3 transcription via the NM_005187 promoter by GCN5. Short hairpin RNA

Indexed as

AnimalsCore Binding Factor Alpha 2 SubunitCyclin-Dependent Kinase Inhibitor p21Disease-Free SurvivalG1 Phase Cell Cycle CheckpointsHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMiceMice, KnockoutOncogene Proteins, Fusionp300-CBP-Associated Factorp300-CBP Transcription FactorsPrognosisRecurrenceRepressor ProteinsAML1-ETO fusion protein, humanCBFA2T3 protein, humanCore Binding Factor Alpha 2 SubunitCyclin-Dependent Kinase Inhibitor p21Oncogene Proteins, Fusionp300-CBP-Associated Factorp300-CBP Transcription FactorsRepressor ProteinsRNA, Small InterferingRUNX1 Translocation Partner 1 Protein

Identifiers

PMID31040112
PMCPMC6517668
OpenAlexW2943244154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.